In her multifaceted career, Dr. Jacene holds several prominent positions, including Chief of Molecular Imaging and Theranostics at Beth Israel Deaconess Medical Center, Clinical Director of Nuclear Medicine/PET-CT, and Senior Physician at Dana-Farber Cancer Institute. She also serves as Associate Professor of Radiology at Harvard Medical School. Her diverse roles underscore a strong commitment to pushing the boundaries of nuclear medicine through both clinical excellence and academic rigor, highlighting her capacity to bridge the gap between innovative research and patient-centered care.

One of Dr. Jacene’s primary objectives as president is to reinforce SNMMI as an indispensable resource for its members, spanning the spectrum from foundational basic science research to the highest standards of evidence-based clinical application. She emphasizes the critical importance of fostering an environment where nuclear medicine evolves through interdisciplinary collaboration and robust scientific inquiry, ensuring that the field remains at the forefront of diagnostic and therapeutic modalities.

Dr. Jacene is focused on creating dynamic platforms within SNMMI that encourage active participation and collaboration among members, transcending traditional disciplinary boundaries. By promoting multidisciplinary partnerships, she envisions expanding the reach and influence of nuclear medicine, driving innovations that enhance molecular imaging technologies such as PET-CT and radiopharmaceutical therapies. Her approach involves breaking down silos to facilitate knowledge exchange and accelerate technological advancements.

A major part of her agenda involves advocating for increased awareness and acceptance of nuclear medicine among clinical colleagues and patients alike. She aims to communicate the tangible benefits of these advanced imaging techniques in personalized medicine, emphasizing how molecular imaging enables precise characterization of disease states and therapeutic responses. This strategic communication will help solidify nuclear medicine’s role as a cornerstone of modern clinical practice.

Another critical challenge Dr. Jacene intends to address involves the barriers related to the availability, reimbursement, affordability, and funding of radiopharmaceuticals. These radiotracers are indispensable tools in targeted diagnostic and therapeutic procedures, yet their accessibility remains uneven. Her leadership will concentrate on policy advocacy and operational innovations to ensure broader and timely access to these vital agents, thus enhancing the clinical utility and patient reach of nuclear medicine.

Dr. Jacene’s extensive training and expertise reflect a career dedicated to nuclear medicine and molecular imaging. She earned her medical degree from the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School in New Brunswick, New Jersey. She subsequently completed both her residency and fellowship in nuclear medicine and PET-CT at Johns Hopkins University, Baltimore, where she honed her skills in cutting-edge diagnostic imaging techniques and the evolving applications of radiopharmaceuticals in oncology and beyond.

Her longstanding involvement with SNMMI is marked by significant leadership roles, including chairing the Scientific Program Committee, where she orchestrated innovative transformations to the Annual Meeting format. These changes have led to enhanced member engagement, increased networking opportunities, and a fertile ground for presenting novel research. She has also played a pivotal role in quality assurance, serving as Chair for the Quality of Practice Domain within the SNMMI Value Initiative, and helped establish the Radiopharmaceutical Centers of Excellence Program to standardize and elevate the delivery of radiopharmaceutical therapies.

Dr. Jacene’s research portfolio is both extensive and impactful, focusing predominantly on the application of FDG-PET/CT and other emerging PET tracers for the assessment of cancer biology and therapeutic efficacy. Her investigations delve into functional imaging biomarkers that reveal tumor metabolism, receptor expression, and microenvironmental changes, thereby informing more personalized and adaptive treatment strategies. Furthermore, she explores novel radiopharmaceutical therapies that promise to revolutionize the management of malignancies through targeted molecular interventions.

In addition to more than 100 peer-reviewed scientific publications, Dr. Jacene has authored numerous review articles and book chapters, contributing authoritative perspectives on the evolving landscape of molecular imaging and theranostics. Her scholarship not only advances academic discourse but also aids in translating complex imaging science into practical clinical guidelines and protocols that optimize patient care.

The new SNMMI leadership team for 2026-27 includes other distinguished figures such as Gary Ulaner, MD, PhD, FSNMMI, chosen as president-elect, and Jason S. Lewis, PhD, FSNMMI, as vice president-elect. The SNMMI Technologist Section has also elected Shannon Youngblood, EdD, MSRS, CNMT, RT(CT), as president, with Sara L. Johnson, CNMT, RT(N)(CT), serving as president-elect. Together, this leadership cadre represents a diverse spectrum of expertise poised to drive the society’s mission forward.

SNMMI remains a global scientific and medical organization dedicated to propelling nuclear medicine, molecular imaging, and theranostic precision medicine. Through its efforts, SNMMI facilitates innovations that allow clinicians to tailor diagnostic and therapeutic approaches to individual patients with unprecedented specificity, aiming for optimal outcomes. Dr. Jacene’s presidency symbolizes a sustained commitment to integrating high-caliber research, education, and clinical practice at the forefront of this transformative field.

Subject of Research:
Heather Jacene’s presidency at SNMMI and advancements in nuclear medicine and molecular imaging, including PET-CT innovations and radiopharmaceutical therapy.

Article Title:
Heather Jacene, MD, Named President of the Society of Nuclear Medicine and Molecular Imaging: Advancing the Future of Molecular Imaging and Theranostics

News Publication Date:
June 2026

Web References:
http://www.snmmi.org/

Image Credits:
Courtesy of SNMMI

Keywords:
Molecular imaging, Nuclear medicine, Positron emission tomography, Personalized medicine, Radiopharmaceutical therapy, Theranostics, FDG-PET/CT, Radiopharmaceutical Centers of Excellence, Precision medicine, SNMMI, Cancer imaging, Clinical molecular imaging

The SNMMI Fellowship reflects a rigorous selection process that emphasizes not only distinguished volunteer service to the society but also outstanding achievement in scientific discovery, educational impact, or clinical practice. These criteria ensure that the honorees represent the pinnacle of expertise and leadership, fostering the ongoing evolution of nuclear medicine and molecular imaging techniques that are central to modern precision medicine.

One of the newly inducted Fellows, Dr. Gholam Reza Berenji, currently directs nuclear cardiology at the VA Greater Los Angeles Healthcare System. His academic role as an adjunct professor at the University of Victoria in Canada underscores his commitment to fostering interdisciplinary knowledge transfer. Dr. Berenji’s involvement in multiple SNMMI councils, including the Academic and Cardiovascular Councils and specialized centers of excellence, positions him at the forefront of facilitating cutting-edge research and practice integration in cardiovascular molecular imaging modalities.

Dr. Mehdi Djekidel, another inductee, serves as associate professor of radiology at the Zucker School of Medicine at Hofstra University and practices diagnostic radiology and nuclear medicine at Northwell Health. His leadership roles within the Theranostics Leadership Group and other critical committees highlight his active participation in the development and oversight of radiopharmaceutical therapies and brain imaging initiatives, contributing significantly to the refinement of neuroimaging and personalized treatment paradigms.

In Washington, D.C., Dr. Giuseppe Esposito presides as chief of nuclear medicine at Medstar Georgetown University Hospital and co-directs nuclear medicine services at Medstar Medical Group Radiology. His stewardship on the SNMMI Board of Directors and as chair of the Scientific Program and Education Committee reflects his dedication to advancing scientific education and orchestrating high-impact sessions at annual meetings that disseminate the latest research breakthroughs and clinical protocols widely across the nuclear medicine community.

Distinguished for his contributions to oncologic imaging, Dr. Homer Macapinlac holds the James E. Anderson Distinguished Professorship of Nuclear Medicine at the University of Texas MD Anderson Cancer Center. His longstanding leadership within the SNMMI PET Center of Excellence, including serving as its president, underscores his pivotal role in promoting positron emission tomography applications in cancer diagnostics and therapy management, fostering innovations that enhance tumor detection sensitivity and treatment monitoring.

Professor John Prior, based at Lausanne University Hospital in Switzerland, is renowned for his expertise in nuclear medicine and molecular imaging, where he heads the related department. His multifaceted contributions as a society leader, educator, and prolific speaker at SNMMI conferences have significantly influenced the international scientific discourse, particularly emphasizing molecular imaging’s capacity to revolutionize disease detection and therapeutic strategies on a global scale.

Recognizing the importance of patient advocacy in advancing nuclear medicine, Josh Mailman was honored as an Honorary Fellow. An internationally respected advocate for neuroendocrine tumor patients, Mailman’s pivotal role as the inaugural chair of SNMMI’s Patient Advocacy Advisory Board exemplifies his efforts to bridge the gap between patient communities and medical practitioners, ensuring that patient narratives inform therapeutic innovation and regulatory policies alike.

The 2026 Fellowship also acknowledged the career of Dr. Libero (Lou) Marzella, a former director at the FDA Division of Imaging and Radiation Medicine. Dr. Marzella’s contributions have been instrumental in shaping regulatory frameworks that govern PET radiopharmaceutical drug development. His expertise has not only guided policy in the United States but has also fostered international collaborations that streamline PET imaging agent approval, proving vital for translational research and clinical trial success worldwide.

The upcoming SNMMI president for 2025-26, Dr. Jean-Luc Urbain, will receive Fellowship status after his term, recognizing his extensive leadership across multiple domains within the society. Dr. Urbain’s commitment to international collaboration and educational outreach continues to drive innovation by integrating research, clinical application, and global partnerships, enabling nuclear medicine to address challenges in personalized diagnostics and tailored therapies comprehensively.

Throughout these recognitions, SNMMI reiterates its mission to promote nuclear medicine and molecular imaging as indispensable tools in precision medicine. These imaging techniques exploit radiopharmaceuticals to visualize and measure biological processes at the molecular and cellular levels, providing unparalleled insights into disease mechanisms while facilitating the tailored treatment of conditions ranging from cardiac disorders to complex malignancies.

The integration of theranostics—where diagnostic imaging and therapeutic delivery are fused—represents a paradigm shift in patient care, enabling clinicians to predict, monitor, and optimize treatments based on individualized biological data. The honored Fellows’ varied expertise across PET, radiopharmaceutical therapy, and clinical oncology underscores the dynamic and interdisciplinary evolution of this field.

The SNMMI’s emphasis on Fellow recognition not only celebrates individual excellence but also highlights the collaborative and translational efforts necessary to push the boundaries of nuclear medicine. By fostering a vibrant community of innovators, educators, and advocates, SNMMI ensures that molecular imaging continues to impact patient outcomes profoundly, influencing future healthcare practices globally.

The 2026 Annual Meeting itself, a cornerstone event for the nuclear medicine community, provides an invaluable platform for sharing advancements, debating challenges, and forging partnerships that accelerate scientific discovery. The induction of these Fellows symbolizes the ongoing quest for excellence and the relentless pursuit to harness molecular insights for groundbreaking clinical applications.

As the SNMMI Fellowship cohort grows, the society reinforces its commitment to recognizing those who enhance the knowledge base, clinical capabilities, and patient-centered focus of the nuclear medicine and molecular imaging fields. This prestigious designation serves as an inspiration to both emerging and established professionals dedicated to improving diagnostics and therapies through cutting-edge science.

Subject of Research: Nuclear Medicine, Molecular Imaging, Theranostics, Positron Emission Tomography, Radiopharmaceutical Therapy

Article Title: SNMMI Honors New Fellows Advancing Nuclear Medicine and Molecular Imaging Innovation at 2026 Annual Meeting

News Publication Date: June 2026

Web References: http://www.snmmi.org

Keywords: Nuclear Medicine, Molecular Imaging, Theranostics, Positron Emission Tomography, Radiopharmaceutical Therapy, Personalized Medicine, Oncology Imaging, Regulatory Science, Patient Advocacy

The first of these studies delves deep into the synaptic aftermath of spinal cord injury using state-of-the-art positron emission tomography (PET) imaging paired with a novel synapse-specific tracer. By employing this tracer in rodent models of mild, moderate, and severe spinal injuries, researchers have achieved unprecedented visualization of synaptic loss and neural communication disruptions. Their longitudinal analysis not only maps structural neural degradation but also correlates in vivo PET findings with meticulous ex vivo biochemical assessments. This integrative approach paves the way for enhanced understanding of the dynamic neurobiological sequelae post-injury and identifies potential molecular targets for therapeutic intervention.

Shifting the focus from localized to systemic, another remarkable study employs whole-body PET combined with sophisticated network-based analytics to unravel the complex crosstalk between the brain and peripheral immune system. Using murine models challenged by infections or pharmacologic agents, the investigators track spatiotemporal shifts in systemic inflammation, revealing intricate pathways of immune modulation across multiple organ systems. By leveraging graph theory and network mapping, this research elucidates how immune responses are coordinated at an organism-wide level, fostering new paradigms in understanding neuroimmune communication and inflammatory diseases.

In the realm of oncology, the convergence of targeted alpha radiation and immunotherapy heralds a promising therapeutic frontier for aggressive lymphoma. Experimental investigations in murine lymphoma models explored the synergistic potential of radiopharmaceuticals delivering alpha particles directly to tumor cells alongside immune checkpoint inhibitors. This dual-modality approach demonstrated superior tumor control, attenuation of immune evasion, and extended survival compared to monotherapies. The strategic combination underscores the capacity of precision nuclear medicine to not only eradicate malignancies but also modulate anti-tumor immunity effectively.

Prostate cancer patients stand to benefit from sophisticated imaging predictors that forecast responsiveness to targeted alpha therapies. A retrospective analysis of advanced prostate cancer cases utilized pretreatment PET scans focusing on prostate-specific membrane antigen (PSMA) uptake patterns. By quantifying tumor burden and tracer distribution, researchers identified imaging biomarkers that correlate with prostate-specific antigen (PSA) kinetics, disease progression risks, and overall survival outcomes. This study underscores the critical role of functional imaging in personalizing radionuclide therapy protocols and optimizing patient-specific treatment plans.

In parallel, comparative assessments of imaging modalities for staging intermediate- and high-risk prostate cancer provide invaluable insights into diagnostic accuracy. By juxtaposing PSMA PET/CT, gastrin-releasing peptide receptor (GRPR) PET/CT, and multiparametric magnetic resonance imaging (mpMRI), investigators benchmarked the sensitivities and specificities of each technique against histopathological findings from surgical specimens. The data reveal nuanced strengths and limitations inherent to these modalities, facilitating evidence-based selection of imaging strategies to improve preoperative staging precision and prognostication of recurrence risk.

Addressing technological innovation, a new deep learning-based method promises to revolutionize PET/CT scan alignment, drastically reducing scan duration and radiation exposure. Tested on next-generation long axial field-of-view PET/CT systems with multiple tracers, this approach maintains essential spatial registration and quantitative accuracy despite shortened acquisition times and ultra-low-dose computed tomography scans. By automating and enhancing image co-registration, this advancement holds transformative potential for clinical throughput, patient comfort, and safety.

Neuroendocrine tumors, often challenging to treat effectively, are the focus of a novel theranostic duo integrating matched imaging and therapeutic radiopharmaceuticals. Early-phase clinical evaluation leveraged single-photon emission computed tomography (SPECT/CT) and dosimetry modeling to optimize tumor visualization and establish radiation dose distributions. Insights gained from this meticulous characterization inform personalized alpha-particle therapy scheduling, maximizing efficacy while minimizing collateral toxicity. This theranostic strategy exemplifies the power of molecular imaging in tailoring precise treatment for complex malignancies.

Collectively, these pioneering studies not only illuminate intricate biological processes but also chart new courses for clinical application, driven by synergy between molecular probes, imaging technologies, and computational analytics. The Journal of Nuclear Medicine remains at the vanguard of disseminating research that bridges fundamental science and patient-centered innovation, fortifying the expanding landscape of theranostics and precision medicine.

The commitment to advancing nuclear medicine as a discipline that offers nuanced visualization and targeted intervention is reflected in the broad spectrum of these investigations—from synaptic mapping in neurological injury to systemic immune profiling and targeted oncologic therapies. As researchers continue refining imaging tracers, radiation delivery methods, and analytic tools, the horizon of personalized healthcare draws nearer.

For practitioners, scientists, and clinicians alike, these insights offer tangible pathways to enhance diagnostic confidence, tailor therapeutic regimens, and ultimately elevate patient outcomes. The fusion of molecular imaging, data science, and immunotherapeutics showcased here exemplifies the vibrant interdisciplinary spirit propelling modern medicine forward.

To explore these advancements in detail, visit The Journal of Nuclear Medicine’s official website, and engage with the community on their social media platforms. The Society of Nuclear Medicine and Molecular Imaging (SNMMI) continues to foster dialogue and innovation, enabling these scientific breakthroughs to transition swiftly from bench to bedside.

Subject of Research: Advanced Molecular Imaging Techniques and Theranostic Applications in Neurology and Oncology
Article Title: Scanning Synapses After Spinal Cord Injury; Brain–Body Immune Cross-Talk Revealed with Whole-Body Imaging; Pairing Alpha Radiation and Immunotherapy for Aggressive Lymphoma; PET Imaging Predictors for Targeted Alpha Therapy in Prostate Cancer; Comparing Imaging Tools to Stage Prostate Cancer; Smarter PET/CT Alignment for Faster, Lower-Dose Whole-Body Imaging; A New Theranostic Pair for Imaging and Treating Neuroendocrine Tumors
News Publication Date: February 6, 2026
Web References:
https://doi.org/10.2967/jnumed.125.271236
https://doi.org/10.2967/jnumed.125.271514
https://doi.org/10.2967/jnumed.125.270515
https://doi.org/10.2967/jnumed.125.270677
https://doi.org/10.2967/jnumed.125.271410
https://doi.org/10.2967/jnumed.125.270420
https://doi.org/10.2967/jnumed.125.270083
Keywords: Molecular imaging, Positron emission tomography, Personalized medicine, Theranostics, Alpha radiation therapy, Prostate cancer imaging, Neuroendocrine tumors, Immune system imaging, PET/CT scan alignment, Radiation dosimetry, Immunotherapy, Neuroimaging

Kawasaki disease is a multifaceted condition characterized by inflammation of the blood vessels, leading to potential coronary artery damage. The identification of osteopontin as a major player in this pathology offers a new avenue for exploration. Osteopontin is known to be involved in various cellular processes including inflammation, tissue remodeling, and immune response. Understanding its role presents a unique opportunity to intercede in the disease’s progression, potentially improving outcomes for affected patients.

By leveraging the unique properties of gold nanoparticles, the researchers are investigating a novel imaging technique that could enhance the visualization of osteopontin within affected tissues. Gold nanoparticles are renowned for their biocompatibility and tunable optical properties, which make them an ideal candidate for applications in nanomedicine. The capacity to specifically target osteopontin could not only elevate imaging capabilities but might also pave the way for targeted therapeutics that can selectively deliver drugs to inflamed areas.

The mechanistic aspect of this study focuses on the STAT3 signaling pathway, which has emerged as a critical regulator in numerous cellular functions. The researchers meticulously dissected how STAT3 modulates the expression of Col1 in the presence of osteopontin. Col1 plays a vital role in the structural integrity of tissues, and its aberrant regulation can lead to significant complications in Kawasaki disease, including aneurysm formation. By targeting this pathway with gold nanoparticles, the study aims to reveal the interconnected mechanisms that underlie the pathology of Kawasaki disease.

Notably, the study employs advanced imaging techniques to demonstrate how gold nanoparticles enhance the visualization of osteopontin expression in real-time. The researchers utilized a variety of in vitro and in vivo models to simulate the inflammatory environment of Kawasaki disease. This approach not only underscores the nanoparticles’ effectiveness in imaging but also their potential as therapeutic agents. Through targeted delivery mechanisms, gold nanoparticles may provide a platform for delivering anti-inflammatory drugs directly to the site of interest, minimizing systemic side effects.

Beyond the immediate implications for Kawasaki disease, this research offers insights that could be extrapolated to other inflammatory conditions. The role of osteopontin and the involvement of the STAT3 pathway implicate broader therapeutic targets within various pathologies that feature similar inflammatory profiles. Consequently, the findings from this research may open doors for the development of diagnostic and therapeutic strategies applicable across a wide range of immune-mediated diseases.

In addition to the scientific advancements, this study emphasizes the importance of multidisciplinary collaboration in tackling complex medical problems. By bringing together experts from oncology, nanotechnology, and cardiovascular research, the team was able to explore this issue from several critical angles. The integration of knowledge and expertise across different fields exemplifies how novel solutions can emerge from innovative partnerships.

Public health implications are substantial, as Kawasaki disease can often lead to lifelong health challenges, including coronary artery disease. By improving diagnostics and potentially offering new treatment avenues, researchers are optimistic about the future for pediatric patients suffering from this condition. The hope is that with continued exploration of these mechanisms, more effective and personalized treatment strategies can emerge.

Moreover, the avenues for future research are expansive. The scientists propose that further investigations should focus on optimizing the nanoparticles for enhanced targeting efficacy. This could involve modifications to the gold nanoparticles’ surface chemistry to improve binding affinity to osteopontin or to enhance their stability within biological systems. The future of this research holds promise not only for pediatric cardiology but for the broader field of regenerative medicine.

As the study unfolds, it invites a wider audience to consider the implications of nanotechnology in everyday healthcare, particularly in the context of chronic diseases. The quest for innovative applications of nanoparticles in diagnostics and therapeutics represents a significant leap toward personalized medicine. As research continues to advance, the synthesis of cutting-edge technology with traditional medical approaches may generate groundbreaking developments that redefine how we treat previously challenging conditions.

In conclusion, the intricate interplay between osteopontin, gold nanoparticles, and the STAT3 signaling pathway illuminates a cutting-edge approach for addressing Kawasaki disease. The potential to enhance molecular imaging while concurrently exploring therapeutic benefits epitomizes the dynamic convergence of technology and medicine. This research not only signifies a promising advancement for Kawasaki disease management but may also herald a new era in treating a myriad of inflammatory diseases.

Subject of Research: Kawasaki Disease and Osteopontin Targeting Using Gold Nanoparticles

Article Title: Targeting osteopontin with gold nanoparticles for enhanced molecular imaging in Kawasaki disease: in-depth mechanistic study of STAT3 signaling in Col1 regulation.

Article References:

Song, J., Zhang, R., Li, Q. et al. Targeting osteopontin with gold nanoparticles for enhanced molecular imaging in Kawasaki disease: in-depth mechanistic study of STAT3 signaling in Col1 regulation.
J Transl Med (2026). https://doi.org/10.1186/s12967-026-07683-4

Image Credits: AI Generated

DOI:

Keywords: Kawasaki Disease, Osteopontin, Gold Nanoparticles, Molecular Imaging, STAT3 Signaling, Collagen Type I, Nanomedicine.

Wonhwa Cho’s recognition stems from his remarkable work elucidating the intricate mechanisms of lipid-protein interactions, shedding new light on a complex facet of cellular biology that has far-reaching implications for lipid-targeted drug discovery. By dissecting these molecular dialogues at an unprecedented level of detail, Cho has opened the door to novel therapeutic strategies focused on lipid-related pathways that play critical roles in numerous diseases.

Central to Cho’s research is an innovative experimental framework that leverages cutting-edge biophysical techniques to overcome longstanding barriers in lipid research. His multifaceted approaches combine high-resolution spectroscopy, advanced molecular imaging, and sophisticated biophysical modeling to interrogate lipid assemblies and their dynamic interplay with membrane proteins. This has cultivated a new era of mechanistic insights into the physicochemical principles underlying lipid-mediated cellular regulation.

The significance of lipid-protein interactions in cellular function cannot be overstated. Lipids, once considered mere structural components of membranes, are now recognized as active participants in signaling cascades and homeostatic control. Cho’s mechanistic elucidations decode how specific lipid species orchestrate the localization, conformation, and activity of membrane proteins that govern processes such as signal transduction, membrane trafficking, and metabolic regulation.

In particular, Cho’s spotlight on lipid microdomains and their role in assembling signaling platforms provides a critical link between molecular architecture and pathological states. Through meticulous experimentation, he has demonstrated how dysregulation of these lipid-protein assemblies contributes to disease pathology, including neurodegenerative disorders and metabolic syndrome, thus identifying new molecular targets for therapeutic intervention.

The impact of Cho’s work extends beyond fundamental biology into translational research. By defining precise molecular interactions, his findings lay the groundwork for the rational design of lipid-targeted drugs, which can modulate membrane protein function with high specificity. This concept revolutionizes traditional drug discovery paradigms, shifting the focus from protein-centric approaches to integrated lipid-protein targeting strategies.

BPS President Lynmarie Thompson, from the University of Massachusetts Amherst, applauded Cho’s pioneering spirit: “Wonhwa has pioneered new and innovative experimental approaches to overcome obstacles and make breakthrough discoveries that have revolutionized lipid research and laid the foundation for new translational research on lipid-targeting drug discovery.” Thompson emphasized that Cho’s high-impact contributions will continue to influence cell biology profoundly and inspire future breakthroughs.

The Biophysics of Health and Disease Award, inaugurated by the Biophysical Society, recognizes distinguished scientists who have significantly advanced our understanding of the root causes and mechanisms of disease or have developed transformative means to treat or prevent illnesses. Cho’s achievements embody the award’s mission, reflecting a fusion of rigorous biophysical research with pressing clinical relevance.

Cho’s methodologies incorporate innovative tools such as cryo-electron microscopy coupled with cutting-edge computational simulations, allowing precise visualization and dynamic modeling of lipid-protein complexes in physiologically relevant contexts. This convergence of experimental and theoretical techniques has overcome previous technological limitations, enabling an unprecedented clarity in understanding membrane dynamics.

Furthermore, the conceptual advances from Cho’s studies challenge existing dogmas about membrane fluidity and organization, revealing a highly orchestrated landscape where lipids actively sculpt protein function rather than act as passive environmental factors. This paradigm shift fuels a deeper comprehension of cellular heterogeneity and signaling specificity in health and disease.

Another notable facet of Cho’s research is his interdisciplinary collaboration, combining insights from chemistry, physics, molecular biology, and pharmacology to solve complex biological problems. This integrative approach exemplifies the essence of biophysics—bridging fundamental science with therapeutic innovation to tackle some of the most stubborn health challenges.

As the field anticipates the upcoming Biophysical Society Annual Meeting, where Cho will receive this distinguished accolade, the broader scientific community recognizes that his work epitomizes the transformative potential of biophysics in modern medicine. His contributions not only advance scientific knowledge but also promise to accelerate the development of novel interventions that could reshape treatment landscapes.

The Biophysical Society, established in 1958, continues its legacy of fostering a vibrant global community of scientists dedicated to exploring the interface of physical and life sciences. With over 6,500 members worldwide, the Society remains a pivotal platform that propels innovation through its annual conferences, high-impact publications, and outreach initiatives, championing research like Cho’s that bridges molecular understanding and human health.

As lipid-targeted drug discovery evolves into a frontier of personalized medicine, researchers inspired by Cho’s work are poised to explore the vast potential of exploiting lipid-protein interactions therapeutically. The implications for chronic diseases, cancer, neurological conditions, and beyond are profound, signaling an exciting era where biophysics not only informs fundamental science but also transforms clinical practice.

Subject of Research: Mechanistic elucidation of lipid-protein interactions related to lipid-targeted drug discovery and disease pathogenesis.

Article Title: Not provided.

News Publication Date: Not provided explicitly; inferred as early 2026 based on the announcement timeline.

Web References: Not provided.

References: Not provided.

Image Credits: Not provided.

Keywords: Biophysics, Lipid-protein interactions, Lipid-targeted drug discovery, Disease mechanisms, Membrane biology, Biophysical Society, Cellular signaling, Translational research.

The synthesis of this ^18F-labeled compound marks a significant milestone in the realm of radiopharmaceuticals. The design and execution of such a synthesis require intricate knowledge of organic chemistry and radiochemistry, as the addition of fluorine-18—a positron-emitting isotope—demands precise handling due to its rapid decay and short half-life. The team, led by researchers Miao, Yang, and Peng, undertook meticulous steps to craft this imaging agent, which is not only optimized for labeling but also effective for targeting COX-2 expression.

COX-2, an enzyme that plays a critical role in inflammation and pain, is overexpressed in many cancers, making it an attractive target for diagnostic imaging. Previously, imaging techniques lacked specificity, often leading to ambiguous results. This new ^18F-labeled derivative seeks to address that gap by enabling clearer and more differentiated imaging of COX-2 levels in vivo. Such an advancement can lead to improved diagnostic accuracy, thereby allowing clinicians to tailor treatments more effectively based on the specific inflammatory profiles present in tumors or other tissues.

The preclinical evaluation of this ^18F-labeled 1,5-diarylpyrrole derivative included a series of detailed studies involving binding affinities and biological evaluations. These studies confirmed not only the capability of the compound to bind selectively to COX-2, but also its favorable pharmacokinetic properties. This is essential because optimal imaging agents need to have a balance between tissue retention and rapid clearance from the bloodstream to ensure clear imaging results.

Assessment of the biological activity revealed promising findings. Miao and colleagues conducted experiments that demonstrated significant uptake of the compound in COX-2 overexpressing tissues while minimizing accumulation in non-target organs. This selectivity is crucial for accurate imaging, as it mitigates the likelihood of false positives that could stem from background noise in the imaging data. The preclinical studies provide a strong foundation for the future application of this compound in clinical settings.

Advanced imaging techniques, such as positron emission tomography (PET), are increasingly being employed in conjunction with these novel agents to visualize biochemical processes in real time. The developed ^18F-labeled 1,5-diarylpyrrole not only shows promise as a reliable imaging marker for COX-2 expression, but it also represents a stepping stone towards personalized medicine. By providing insights into individual patient profiles, it allows for more informed decisions regarding treatment approaches, ultimately improving patient outcomes.

In terms of potential applications, the compound’s ability to visualize COX-2 expression could have far-reaching impacts across oncology and rheumatology. In oncology, for instance, it could be used to evaluate tumors’ inflammatory microenvironments, guiding oncologists in administering targeted therapies that inhibit COX-2 or in determining the most effective anti-inflammatory agents as part of a combination therapy. In rheumatology, tracking COX-2 levels could lead to a better understanding of disease progression in conditions such as rheumatoid arthritis, allowing for proactive management strategies.

Moreover, the need for translatable research to the clinic cannot be overstated. As the team prepares to transition this agent from preclinical studies to human trials, the collected data will be instrumental in attracting collaboration with clinical researchers and pharmaceutical companies interested in developing adjunct therapies utilizing COX-2 inhibitors. This pathway not only improves the therapeutic landscape but also reinforces the importance of interdisciplinary collaboration in the realms of chemistry, biology, and clinical medicine to facilitate innovative discoveries.

Besides the immediate clinical implications, this research signifies broader trends within the scientific community towards the development of personalized diagnostic tools. With the increasing appreciation for individualized treatment plans, compounds like the one synthesized by Miao et al. could very well set the standard for future molecular imaging modalities that are tailored to specific biomarkers. This can transition the focus of diagnostics from a one-size-fits-all approach to more scientifically grounded methodologies that prioritize patient-specific data.

As we move forward, the success of such imaging agents could pave the way for future compounds targeting other critical enzymes or pathways implicated in various diseases. The potential for similar strategies to be adopted across other biomarkers suggests a burgeoning field ripe with possibilities. As more molecular targets are elucidated and understood, it will become increasingly feasible to design targeted imaging agents, effectively bridging the gap between basic scientific research and clinical application.

Finally, the future of molecular imaging looks incredibly promising with the continued development of compounds such as this novel ^18F-labeled 1,5-diarylpyrrole derivative. Through meticulous research and the unyielding pursuit of innovation, scientists are not only enhancing imaging techniques but are also fundamentally transforming the landscape of disease diagnosis and management. As the field progresses, it will certainly result in improved clinical outcomes, further personalized medicine endeavors, and a healthier future for patients across the globe.

Subject of Research: Development of an ^18F-labeled 1,5-diarylpyrrole derivative for imaging COX-2 expression.

Article Title: Synthesis and preclinical evaluation of an ^18F-labeled 1,5-diarylpyrrole derivative for imaging of COX-2 expression.

Article References:

Miao, W., Yang, M., Peng, Z. et al. Synthesis and preclinical evaluation of an ¹⁸F-labeled 1,5-diarylpyrrole derivative for imaging of COX-2 expression. Mol Divers (2025). https://doi.org/10.1007/s11030-025-11328-x

Image Credits: AI Generated

DOI: Not Available

Keywords: COX-2, molecular imaging, ^18F-labeled derivative, radiopharmaceuticals, PET, personalized medicine, oncology, rheumatology, inflammation, diagnostics.

Among these cutting-edge investigations, one of the most notable contributions involves the development of a novel PET imaging agent specifically designed to unmask liver tumors that often remain hidden following conventional treatment strategies. The research introduces a radiotracer that selectively binds to CD24, a glycoprotein highly expressed on the surface of malignant liver cells. This molecular targeting mechanism enables the selective visualization of CD24-positive liver tumors with high fidelity in preclinical murine models. By leveraging the tracer’s ability to discriminate malignant tissue from healthy liver structures, this tool promises to revolutionize the clinical monitoring of hepatocellular carcinoma, enhancing early detection of residual or recurrent disease.

Liver cancer remains one of the most difficult malignancies to surveil post-therapy due to the complex, regenerative nature of hepatic tissue and the limitations of existing imaging modalities. Precision PET imaging agents, such as the CD24-targeted tracer introduced in this work, represent a tectonic shift by coupling molecular specificity with functional imaging. This dual approach not only facilitates the localization of tumor cells with unprecedented accuracy but also lays the foundation for real-time assessment of tumor biology and treatment responsiveness.

Complementing this advance in liver oncology, a separate investigation examines the heterogeneous response patterns of prostate cancer metastases in patients undergoing systemic therapy. Utilizing PSMA PET/CT scanning—a technique that capitalizes on the overexpression of prostate-specific membrane antigen (PSMA) on prostate cancer cells—researchers have uncovered a phenomenon termed interlesional progression, where individual metastatic lesions within the same patient exhibit divergent therapeutic responses. This nuanced insight challenges the prevailing assumption of uniform tumor behavior and emphasizes the necessity for lesion-level assessment to predict clinical outcomes more accurately.

Importantly, the identification of interlesional progression as a prognostic signpost correlates strongly with shortened patient survival, providing a critical window for early intervention modification. Through dynamic and spatially resolved PET imaging, clinicians may soon be able to tailor therapies at an unprecedented level, abandoning a one-size-fits-all approach in favor of personalized regimens that address the molecular heterogeneity intrinsic to metastatic prostate cancer.

The capacity of molecular imaging techniques to unveil such complex tumor dynamics underscores the transformative potential of nuclear medicine in precision oncology. By offering a noninvasive, quantitative, and spatially detailed portrayal of tumor behavior, PET imaging is emerging as an indispensable tool in the evolving landscape of cancer care.

Beyond malignancies, the realm of neurodegenerative diseases with cardiac involvement has also seen important strides, as demonstrated by research into Friedreich ataxia—a rare genetic disorder characterized by progressive neurodegeneration and cardiomyopathy. Given the lack of effective biomarkers to monitor disease progression, researchers applied an innovative PET imaging approach utilizing a radiolabeled compound sensitive to mitochondrial activity, a key pathological hallmark of Friedreich ataxia-afflicted cardiac tissue.

This mitochondrial-focused tracer enabled visualization of diminished metabolic function in the hearts of both rodent models and human subjects afflicted with the disease. The implications of this finding are profound, as tracking mitochondrial dysfunction noninvasively paves the way not only for improved diagnostic clarity but also for the real-time evaluation of therapeutic interventions aimed at preserving cardiac health in these patients. This work exemplifies the intersection of molecular imaging and precision medicine, as it addresses a significant unmet clinical need with tailored diagnostic technology.

Collectively, these studies echo the overarching mission of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), which publishes JNM and champions the advancement of molecular imaging and theranostics. Theranostics—a portmanteau of therapy and diagnostics—embodies the paradigm shift toward individualized medical approaches where diagnostic precision directly informs targeted therapeutic strategies.

In the context of the latest JNM publications, the convergence of new radiotracer development, sophisticated PET imaging protocols, and the elucidation of disease heterogeneity heralds a new era in which physicians can tailor interventions with unmatched specificity and efficacy. As imaging technologies evolve, so too does their capacity to untangle complex biological networks in vivo, providing insights that transcend morphology to encompass cellular and molecular phenotypes.

The integration of these imaging techniques into clinical workflows is poised to directly impact patient outcomes by enabling early detection of treatment resistance, refined risk stratification, and accurate monitoring of therapeutic efficacy. Furthermore, the capability to image cellular processes such as mitochondrial dysfunction offers new vistas for studying pathophysiology beyond oncology, expanding nuclear medicine’s reach into neurology and cardiology.

Investigation of tumor microenvironments, ligand-receptor interactions, and intracellular metabolic pathways through these molecular imaging modalities opens avenues for pharmaceutical innovation. By facilitating biomarker-driven clinical trials, these technologies accelerate the development of next-generation therapeutics with precise mechanisms of action, assessed via reliable, noninvasive imaging endpoints.

The future of nuclear medicine lies in the continuous refinement of molecular probes designed for specificity, stability, and minimal toxicity, paired with imaging platforms capable of quantifying tracer kinetics accurately and reproducibly. The studies published in JNM epitomize this trajectory, proving the clinical utility of molecular imaging tools in unraveling diseases that have traditionally posed diagnostic dilemmas.

Clinicians and researchers are encouraged to explore these publications further on the Journal of Nuclear Medicine website, where the full-text articles detail the underlying methodologies, radiochemistry, animal models, and early human trials driving these innovations. The SNMMI remains committed to disseminating knowledge that empowers the medical community to harness nuclear medicine’s full potential in advancing patient care.

In addition to offering a platform for novel research, JNM’s continuous updates and social media presence ensure timely communication of breakthroughs, facilitating rapid adoption and collaboration across disciplines. This dynamic interface between research and clinical application is central to realizing the promise of personalized imaging and therapy in the coming years.

For direct inquiries or interview opportunities concerning the latest research, media representatives may contact Susan Martonik at smartonik@gmail.com or via cell at 703-303-7789.

Subject of Research: Molecular imaging innovations in cancer detection, tumor heterogeneity in prostate cancer, and cardiac mitochondrial dysfunction in Friedreich ataxia.

Article Title: New Imaging Tool Targets Hidden Liver Tumors; Tumor Response Patterns Offer Clues to Prostate Cancer Outcomes; Imaging Heart Health in Friedreich Ataxia.

News Publication Date: August 1, 2025.

Web References:

• https://doi.org/10.2967/jnumed.125.270167
• https://doi.org/10.2967/jnumed.125.269729
• https://doi.org/10.2967/jnumed.124.268698
• https://jnm.snmjournals.org/
• https://www.snmmi.org/

Keywords: Molecular imaging, medical imaging, positron emission tomography, liver cancer, prostate cancer, Friedreich ataxia, mitochondrial imaging, radiotracer development, tumor heterogeneity, theranostics, precision medicine, nuclear medicine

The first study introduces an innovative positron emission tomography (PET) tracer, carbon-11 labeled HSP990 (^11C-HSP990), developed specifically to image the molecular chaperone protein heat shock protein 90 (Hsp90) in the brain. Hsp90 plays a pivotal role in maintaining neuronal proteostasis and cellular health. Through meticulous preclinical evaluation in rodents and non-human primates, complemented by studies on human postmortem brain tissue, researchers demonstrated a marked reduction in Hsp90 levels in Alzheimer’s disease. This decline suggests Hsp90 could serve as a sensitive and early biomarker for neurodegeneration, potentially transforming our ability to monitor disease progression long before clinical symptoms emerge.

Another crucial contribution focuses on the enigmatic phenomenon of long COVID. Advanced hybrid PET/MRI imaging techniques unveiled previously hidden pathologies in the hearts and lungs of patients suffering from prolonged chest-related symptoms even a year post-infection. The imaging revealed that over fifty percent of these individuals exhibited persistent inflammatory markers within cardiac tissue, while lung abnormalities were nearly ubiquitous. These findings highlight the insidious nature of SARS-CoV-2’s lingering impact and underscore the need for long-term monitoring using sensitive molecular imaging tools to guide therapeutic interventions.

In the oncological realm, a novel immuno-PET/CT tracer utilizing fluorine-18 labeled RCCB6 (^18F-RCCB6) was tested for its ability to target CD70, a surface protein markedly upregulated in nasopharyngeal carcinoma (NPC), a malignancy notoriously difficult to detect in early stages. This imaging compound displayed superior sensitivity compared to standard diagnostic modalities, accurately delineating primary tumors as well as metastatic lymph nodes. By illuminating these cancerous lesions at a molecular level, the technique promises to enhance staging precision, treatment planning, and ultimately patient outcomes.

Progress in targeted radiopharmaceutical therapy is reflected in two reports centered on prostate cancer. A first-in-human clinical trial investigated lutetium-177 labeled HTK03170 (^177Lu-HTK03170), a next-generation radiotherapeutic agent designed to preferentially bind prostate cancer cells, maximizing therapeutic efficacy while minimizing off-target toxicity. The trial aims to establish safe dosing regimens and assess preliminary therapeutic responses in men with advanced, treatment-resistant prostate cancer. Early data herald a new avenue toward personalized, radiopharmaceutical-based management of this disease.

Complementing this, another study showcased the pharmacokinetic stability of a novel compound, lutetium-177 labeled AMTG (^177Lu-AMTG), in the bloodstream of prostate cancer patients. This agent targets gastrin-releasing peptide receptors (GRPR), frequently overexpressed in metastatic prostate tumors. Preliminary results suggest that ^177Lu-AMTG not only remains stable in circulation but also offers superior imaging capabilities to detect elusive metastatic foci that evade current diagnostics, heralding enhanced detection and treatment strategies.

Innovative delivery techniques also entered the spotlight with a report on intratumoral administration of iodine-124 radiolabeled Omburtamab (^124I-Omburtamab) in pediatric patients with brainstem tumors. This approach circumvents the formidable blood-brain barrier, enabling direct radiation delivery at high doses precisely to malignant tissue. Early imaging data revealed extensive tumor coverage with targeted radioactivity, offering fresh hope for children afflicted with these highly resistant neoplasms, where conventional therapies have limited success.

Adding to the innovation, researchers developed an advanced PET imaging method that repurposes the ubiquitous cancer tracer fluorodeoxyglucose labeled with fluorine-18 (^18F-FDG) to quantitatively map blood flow throughout the body. The technique provides rapid and high-resolution imaging comparable to specialized perfusion tracers but benefits from the widespread availability and familiarity of ^18F-FDG. This breakthrough opens pathways to noninvasively investigate vascular health and tissue perfusion in organs including the brain, heart, and tumors, facilitating personalized diagnosis and monitoring.

Collectively, these studies epitomize the fusion of molecular biology, radiochemistry, and clinical innovation that defines modern nuclear medicine. They reinforce the importance of precision imaging and targeted radiotherapy in tackling complex diseases at an unprecedented molecular scale. As the momentum builds, these advances not only promise enhanced diagnostic accuracy and therapeutic outcomes but also exemplify the ongoing evolution towards truly personalized medicine.

The implications are profound: from early detection of Alzheimer’s disease before irreversible damage accrues, to unraveling the subtleties of post-viral syndromes, to refining cancer diagnosis and treatment on a patient-by-patient basis. Researchers and clinicians alike stand at the threshold of a new paradigm where noninvasive, molecular-level visualization and treatment guide every stage of patient care with unparalleled precision. The future of nuclear medicine has never looked brighter.

For those interested in delving deeper into these pioneering studies, visit The Journal of Nuclear Medicine’s website and join the vibrant academic community driving these innovations. Follow their social media channels to stay updated on emerging breakthroughs that continue to reshape the landscape of molecular imaging and theranostics globally.

Subject of Research: Molecular imaging and targeted radiopharmaceutical therapies for neurodegenerative diseases, long COVID, head and neck cancer, prostate cancer, and pediatric brain tumors.

Article Title: Multiple studies on novel imaging agents and targeted radiotherapies are published ahead-of-print in The Journal of Nuclear Medicine.

News Publication Date: May 2, 2025

Web References:

• https://doi.org/10.2967/jnumed.124.268961
• https://doi.org/10.2967/jnumed.124.268980
• https://doi.org/10.2967/jnumed.125.269585
• https://doi.org/10.2967/jnumed.124.269064
• https://doi.org/10.2967/jnumed.124.269132
• https://doi.org/10.2967/jnumed.124.267995
• https://doi.org/10.2967/jnumed.124.268706

Keywords: Molecular imaging, medical imaging, PET tracers, Alzheimer’s disease biomarkers, long COVID, nasopharyngeal carcinoma, prostate cancer radiotherapy, pediatric brain tumor treatment, precision medicine, theranostics, radiopharmaceuticals, PET/MRI.